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The etiology of Prostate Cancer (PCa) is largely unknown. Several factors such as ethnicity, family 
history, and age have been shown to be associated with increased risk of Prostate Cancer. There is 
emerging evidence that polymorphic genes may modulate effects of endogenous androgens or 
environmental toxicants on Prostate Cancer risk. There have been reports that polymorphisms in the 
promoter regions of cytokine genes may influence prostate cancer development via regulation of the 
antitumor immune response and/or pathways of tumor angiogenesis. IL-4 an anti-inflammatory 
cytokine plays a key role in activation and differentiation of B-cells, mast cells, erythroid progenitors 
and the development of the Th-2 subset of lymphocytes. Th2 cytokines such as IL-4, IL-2 and IL-10 
primarily supports antibody production. IL-4 is also known to inhibit macrophage activation and 
therefore may be involve in cancer. In this case control study 150 prostate cancer patients and equal 
number of age matched two control groups that includes, one hundred fifty individuals diagnosed 
with Benign prostate hyperplasia (BPH) and 150 health individuals were recruited. The objective of 
this study was to evaluate the effect of IL-4 VNTR on risk of prostate cancer among north Indian 
population. The PCR (polymerase chain reaction) were utilized to identify the three genotypes of IL-4 
VNTR gene. Statistically significant increased risk of prostate cancer was associated with individuals 
that carry the p2/P2 genotypes (OR=2.45 95%CI=0.98-6.23, p< 0.05). 
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INTRODUCTION  
 
Prostate cancer, unlike cancers of other sites, often has 
a very indolent natural history. Whereas patients with 
any other curable cancer would automatically be offered 
radical treatment, “watchful waiting” has been a 
recognised approach to managing prostate cancer, with 
acceptable  results  in  selected   patients (Albertsen  et  
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al.,1998).  Prostate  cancer  (PCa) is the most common  
noncutaneous cancer among men, accounting for 10% 
of male cancer-related death (Jemal et al., 2009). The 
etiology of PCa is largely unknown, although multiple 
environmental and lifestyle factors such as ultraviolet 
irradiation, smoking, and diet might increase the risk of 
the disease (Grant, 2004). However, not all of those who 
have been   exposed   to  these  risk  factors  will 
develop PCa, suggesting interindividual differences in 
susceptibility.   These  differences   could,  in  part,   be  
 
 
 
 
caused by genetic variations, such as single nucleotide 
polymorphisms in the DNA repair gene that increase 
susceptibility to the DNA damage resulting from 
carcinogens (Goode et al., 2002).  Prostate cancer is a 
common condition worldwide. Different geographical 
regions have varying incidence and mortality. Globally, 
prostate cancer is the sixth most common cancer, and 
the third most common cancer in men in developed 
countries. The risk of prostate cancer is increased by 
African-American ethnicity, increasing age, positive 
family history, and other factors such as diet. 
Nonetheless, the causes of prostate cancer are not well 
understood compared with other common cancers like 
lung and breast cancer (Kumar et al., 2004). There have 
been reports that polymorphisms in the promoter regions 
of cytokine genes may influence prostate cancer 
development via regulation of the antitumor immune 
response and/or pathways of tumor angiogenesis 
(McCarron et al.,2002). Single nucleotide polymorphisms 
or SNPs and variable number of tandem repeats (VNTR) 
are common type of polymorphisms. The variants of 
DNA sequence can have a major impact on how 
humans respond to disease. Moreover environmental 
insults such as bacteria, viruses, toxins, and chemicals; 
may increase the risk of PCa. SNPs do not cause 
disease, but they can help determine the likelihood that 
a particular individual may develop a particular disease 
(Kesarwani et al., 2008). IL-4 an anti-inflammatory 
cytokine plays a key role in activation and differentiation 
of B-cells, mast cells, erythroid progenitors and the 
development of the Th-2 subset of lymphocytes. Th2 
cytokines such as IL-4, IL-2 and IL-10 primarily supports 
antibody production. IL-4 is also known to inhibit 
macrophage activation and therefore, may be involve in 
cancer. A variable number of tandem repeat (VNTR) of 
70 base pair repeat is situated in third intronic region of 
the IL-4 gene. Three repeat allele is most common and 
two repeat allele is rare. There is another much rare 
allele of four repeat, which is reported only in few 
populations (Kesarwani et al., 2008). Three repeat allele 
is known to be high producer of IL-4 (Nakashima et al., 
1999). The IL-4 gene is located on the long arm of 
chromosome 5 (q23–31) in a cluster of other cytokine 
genes (IL-3, -5, -9, -13, and -15, granulocyte colony-
stimulating factor, and interferon regulatory factor) (Le 
Beau et al., 1998). It is also a key T helper-2 cytokine 
that downregulates and upregulates CCR5 and CXCR4 
(Chemochine receptors), respectively, the main 
coreceptors for HIV (Soruano et al., 2005). Earlier 
studies have reported that IL-4 inhibits the release of 
inflammatory mediators, such as TNF-α, IL-6, and IL-1α 
from activated monocytes  (Weiss  et al., 2003; Mittal & 
Manchanda, 2007). Interleukin-4 is a key cytokine that 
induces the activation and differentiation of B cells, and 
the development of the Th2 subset of lymphocytes. Th2 
cytokines such as interleukin-4, 6 and 10 primarily 
support antibody production, and many studies have 
confirmed that patients with cancer have high levels of  
 
 
 
 
such cytokines in their serum. Interleukin-4 also inhibits 
macrophage activation and might be involved in cancer 
causations (Sosroseno et al., 1994; Wang et al., 2002). 
Thus, the aim of the present study was to assess the 
effect of this VNTR on the risk of PCa among north 
Indian population. 
 
 
MATERIALS AND METHODS  
 
Characteristics of study subjects  
 
Blood samples from 150 north Indian males with 
prostate cancer were collected in sterile EDTA-K2 
coated non-vacationous tubes (Becton–Dickinson, San 
Jose, CA, USA). The samples were collected at the 
Departments of Urology of the Postgraduate Institute of 
Medical Education and Research (PGIMER), 
Chandigarh, India, the All India Institute of Medical 
Sciences (AIIMS), New Delhi and Government Medical 
College and Hospital, Patiala, Punjab in north India. All 
patients were histological diagnosed carcinoma of the 
prostate confirmed with biopsy studies as well as 
prostate specific antigens (PSA) test. There were 300 
age matched control samples, of which 150 were free 
from any symptom of disease, whereas the rest 150 
were diagnosed with benign prostate hyperplasia (BPH). 
All the samples were not originated from the same 
hospital; however, all of the individuals recruited for this 
study were in the same geographical area. None of the 
patients were given either chemo or radiotherapy before 
providing the sample. The samples were collected by the 
clinical staff of the hospitals concerned. A detailed 
questionnaire designed by the Indian Council of Medical 
Research (ICMR) encompassing details of the disease 
diagnosis, family history, age, smoking and drinking 
status was completed at the time of collection of the 
samples. Besides, the pathological grading and staging 
of the cancer was confirmed from the hospital record. 
Blood samples were stored at -80 
0
C till extraction of 
DNA. Written informed consent was obtained from all 
cases and controls. The study was carried out after 
obtaining approval from the Ethics Committee of the 
PGIMER, Chandigarh, India. 
 
 
Genotyping of IL-4 VNTR 
 
Genomic DNA was extracted from peripheral blood 
lymphocytes by standardized protienase K digestion and 
phenol– chloroform extraction (Sa´enz-Lo´pez et al., 
2008). The IL-4 VNTR was studied by using the 
polymerase chain reaction. A 70 bp variable number 
tandem repeat (VNTR) of IL- 4 gene was amplified by 
using  primers; forward 5’- 
AGGCTGAAAGGGGGAAAGC-3’ and reverse 5’-5’- 
CTGTTCACCTCAACTGCTCC-3’ as described by 
Kesarwani  et al. (2008).  The  PCR  amplification was  
 
 
 
 
performed in 25µl volume containing 100ng of genomic 
DNA, 0.2mM of mixed dNTP, 20p mol of each primer, 
1.5 U Taq polymerase , 10X KCl, 1.5mM MgCl2  and 
19µl of distilled water. The PCR conditions were 1 cycle 
of dnaturation 1 at 95
0
C for 5 minutes, 30 cycles of 
denaturation 2 at 95 
0
C for 45 seconds followed by 1 
cycle of annealing at 58
0
C for 45 seconds, 72
0
C for 45 
seconds, 72
0
C for 2 minutes, 1 cycle each for extension 
1 and 2, respectively, that generated 184 bp designated 
as  P1/P1 and 254 bp for P2/P2 genotypes (Fig 1).  
 
 
Statistical analysis 
 
Relevant data of cases, BPH and health controls such 
as age, inhabitancy, occupation, smoking and drinking 
habits were tabulated. The effect and association of the 
IL-4 VNTR polymorphism on risk of PCa was analyzed 
by computing odds ratio (OR) and 95 % confidence 
interval (CI). The statistical analysis was performed 
using Epi-Info software (Epi-Info, version 3.5.1. Center 
for Disease Control and Prevention, Atlanta, GA, USA, 
August 13, 2008) and software SPSS version 11.5 
(SPSS, Chicago, IL). Chi-square (ᵡ
2
) test was utilized to 
check for the Hardy–Weinberg’s equilibrium. 
Significance was set at p<0.05. 
 
 
RESULTS 
 
The demographic characteristics of study subjects were 
described elsewhere (Berhane, et al.,2010). The 
genotype frequency of IL-4 VNTR in cases, controls and 
BPH study subjects is  given in Figure 2. The frequency 
of the P1/P1 repeat in cases was 54.7% against 62.7% 
in controls. On the other hand, the frequency of the 
heterozygous P1/P2 genotype in cases was 33.3 % 
unlike 31.3 % in controls. The percentage of the rare 2 
repeat homozygous P2/P2 genotype in cases was 12.7 
against 6 in controls. The P1 allelic frequency for cases 
and controls was 0.70 and 0.78, respectively. The P2 
allelic frequency was 0.3 in cases and it was 0.22 in 
controls. P2 allele was associated with statistically 
increased risk for prostate cancer (OR= 1.50, 95 %CI= 
1.02-2.21, p=0.039). 
The number of smoker and non smoker cases, controls 
and BPH study subjects is given in Figure 3.  The OR 
and 95% CI of smoking cases were computed with non 
smoking healthy controls. There was statically no 
significant association between genetic polymorphism of 
IL-4 VNTR smoking and risk of prostate cancer. 
However, statistically non significant risk of prostate 
cancer on smoker cases was associated on P2/P2 
genotype   carriers (OR=1.88, 95%CI=1.15-3.06) 
The     effect    of    alcohol   in   relation   to   IL-
4VNTR   polymorphism     in   cases,   controls   and 
BPH    study   subjects is given in Fig. 4.    Statistically 
nonsignificant      1.65    folds    of      increased     risk  
 
 
 
 
for prostate cancer was associated due to P2/P2 
genotype and alcoholism.  
 
 
DISCUSSION  
 
IL-4 is a prototypic member of Th2 cytokines and is a 
potent anti-inflammatory. It reduces the production of 
proinflammatory cytokines and destructive enzymes by 
monocytes (Chomarat et al., 1995). The IL-4 gene is 
located on the long arm of chromosome 5 (q23–31) 
together with other Th2 cytokine genes and is present in 
a cluster of cytokine genes (IL-3, -5, -9, -13, and -15, 
granulocyte colony-stimulating factor, and interferon 
regulatory factor; (Le Beau et al., 1989). This gene 
contains a variable number of tandem repeat 
polymorphism located in third intron VNTR; (Weiss et al., 
2004). It consists of three 70-bp repeats in intron-3, a 
rare allele with two repeats and much rarer with four 
repeats. It is a growth costimulator for B and T cells, 
mast cells, erythroid progenitors, and myeloid 
progenitors. Previous studies reported that IL-4 inhibits 
the release of inflammatory mediators, such as TNF-α, 
IL-6, and IL-1α from activated monocytes. IL-4 VNTR 
gene polymorphism is reported to be associated with 
rheumatoid arthritis and IL-4 C-589T with asthma (Buchs 
et al., 2000; Walley and Cookson, 1996). In the present 
study the P2 allele of IL-4 VNTR was associated with 
increased risk of prostate cancer risk (OR= 1.50 95% 
CI=1.02-2.21, p <0.05). 
IL-4 serves as growth co-stimulator for a variety of 
cells, at the same time inhibiting the release of 
inflammatory mediators such as TNF-α, IL-6 and IL-1α 
from activated monocytes (Chomarat et al., 1995). IL-4 
has been reported to regulate growth and proliferation of 
different prostatic cells. 
Associations between the 70 bp VNTR allele of IL-4 
and severity of several diseases have been reported 
(Nakashamya et al., 2002). As far as our knowledge 
goes there is no report on IL-4 VNTR and risk of prostate 
cancer, however, Konwar et al. (2008) reported the IL-4 
polymorphism showed significant association with BPH, 
indicating that this gene is likely to be associated with 
this disease. In addition, they found a significant 
association of IL-4 variants with patient responsiveness 
to combined therapy of α-adrenergic blocker 5-α 
reductase inhibitors. This indicated that IL-4 
polymorphism is not only associated in the susceptibility 
of BPH, but also influences drug responsiveness of BPH 
patients, with some yet unknown mechanism. 
It has been previously shown that IL-4 promotes the 
Th2 response and is directly involved in the 
pathogenesis of GN (Furusu et al., 1997; Nakajima et 
al., 1997). Further, Singh et al. (2003), in their study, 
suggested that IL-4 might be directly involved in the 
development of lupus nephritis, particularly 
glomerulosclerosis and chronic renal fibrosis.  Moreover, 
Mittal   et   al. (2004)   reported   that   IL-4  VNTR  was  
 
 
 
 
 
 
Fig.1:  PCR- VNTR representative agarose gel picture of IL-4 gene 
 of HIV seropositive subjects 
Lane 8  100 bp DNA Marker  
Lanes 1 and 7 P1/P1   183 bp 
Lanes 2 nad 4 P1/P2   183 and 253 bp 
Lanes 3,5, and 6 P2/P2 253 bp 
 
 
 
Figure 2. Frequency of the P1/P1, P1/P2/, P2/P2 genotypes and P1 and P2 alleles of  IL-4 gene  
among cases, controls and BPH study subjects.  
 
 
 
 
Figure 3.  The genotype frequency of IL-4 VNTR and smoking status among cases, controls  
and BPH study subjects  
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Figure 4. The genotype frequency of IL-4 VNTR and alcoholic status among cases,  
 controls and BPH study subjects. 
 
 
 
associated with increased risk of end stage renal 
disease. Regarding smoking and alcoholism no 
additional statistically significant association was 
observed in cases.  To exactly indicate the P2/P2 
genotype of IL-4 gene as a risk factor for prostate cancer 
additional study with large sample size in the same 
population and with different genetic background is 
warranted. Moreover, the role of IL-4 anti inflammatory 
cytokine in PCa patients needs to be explained by 
measuring IL-4 level in the serum of patients.   
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